Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva

Gynecologic Oncology

Volumn 106, Issue 3, 2007, Pages 628-630

  Olawaiye, Alexander ^a   Lee, Lisa M ^a   Krasner, Carolyn ^a   Horowitz, Neil ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

EGFR; Erlotinib; Vulvar cancer

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; LOPERAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMORBIDITY; DIARRHEA; DISEASE COURSE; DRUG TARGETING; FEMALE; HUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; VULVA CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VULVAR NEOPLASMS;

EID: 34548133367     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.006     Document Type: Article

References (10)

1. American cancer Society. Cancer facts and figures 2006 (2006), American Cancer Society, Atlanta, GA
2. Berchuck A., Rodriguez G., Kamel A., Soper J.T., Clarke-Pearson D.L., and Bast Jr. R.C. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet. Gynecol. 76 3 Pt. 1 (1990 (Sep)) 381-387
3. Johnson G.A., Mannel R., Khalifa M., Walker J.L., Wren M., Min K.W., et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol. 65 3 (1997 (Jun)) 425-429
4. DiSaia P., and Creasman W. Clinical gynecologic oncology. 5th ed. (1997), Mosby-Year Book, St. Louis
5. Ghurani G.B., and Penalver M.A. An update on vulvar cancer. Am. J. Obstet. Gynecol. 185 2 (2001 (Aug)) 294-299
6. Moore D.H., Thomas G.M., Montana G.S., Saxer A., Gallup D.G., and Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 42 1 (1998 (Aug 1)) 79-85
7. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353 2 (2005 (Jul 14)) 133-144
8. Lynch T..J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 21 (2004 (May 20)) 2129-2139
9. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004 (Jun 4)) 1497-1500
10. Wu X., Xin Y., Yao J., Hasui K., Tsuyama S., Yonezawa S., et al. Expression of epithelial growth factor receptor and its two ligands, transforming growth factor-alpha and epithelial growth factor, in normal and neoplastic squamous cells in the vulva: an immunohistochemical study. Med. Electron. Microsc. 34 3 (2001 (Sep)) 179-184